Mineralys Therapeutics closed at $15.55 on Nov 2, down 14.47%, within 0.0% of its 52-week closing low. Volume of 4.6M shares was 2.99× its 20-day average (well above normal).
Split-adjusted performance: -34.2% over one month, -47.6% over six months, -62.2% over one year.
Short interest was 7.4M shares at the Oct 15 settlement, down 4.7% from the prior report (11.6% of float, 5.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MLYSMineralys Therapeutics | $15.55 | −14.47% | −47.6% | — | — | — | $1.37B | |
| ANABAnaptysBio | $46.91 | −2.84% | −32.8% | −8.0% | −206.9% | — | $1.40B | Compare |
| RAPPRapport Therapeutics | $25.13 | +0.32% | −29.3% | — | — | — | $1.42B | Compare |
| DMRADamora Therapeutics | $21.60 | +0.51% | — | — | — | — | $1.33B | Compare |
| KARDKardigan | $14.21 | +0.57% | — | — | — | — | $1.33B | Compare |
| KRSAKorsana Biosciences | $31.66 | +5.04% | — | — | — | — | $1.44B | Compare |
| ETONEton Pharmaceutcials | $50.81 | −2.63% | +68.5% | +98.6% | 30.8% | 114.5 | $1.45B | Compare |
| PCRXPacira BioSciences | $36.40 | +0.03% | +47.4% | +6.2% | 2.4% | 99.2 | $1.45B | Compare |
| OMEROmeros | $17.83 | −3.31% | +19.6% | — | 46.4% | 10.3 | $1.29B | Compare |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
